Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20945434 | 0.84 | RAC1 (0.60) | HSD17B10MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL20945441 | 0.84 | MAPT (0.47) | MEN1KMT2ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL20966315 | 0.82 | HIF1A (0.53) | MEN1KMT2ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL20945460 | 0.79 | MAPT (0.61) | MEN1KMT2ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL20966312 | 0.76 | TGFBR1 (0.48) | KDM4EMAPTLMNATHRB | |
| SCHEMBL20945462 | 0.75 | MAPT (0.45) | MEN1KMT2ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL20966317 | 0.75 | RAC1 (0.71) | HSD17B10MEN1KMT2AALDH1A1EGFR | |
| SCHEMBL29920372 | 0.75 | RAC1 (0.71) | HSD17B10MEN1KMT2AALDH1A1EGFR | |
| SCHEMBL20945446 | 0.74 | MAPT (0.66) | MEN1KMT2ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL20945457 | 0.73 | MAPT (0.41) | HSD17B10MEN1KMT2ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11446299-B2 | Carbazole EHop-016 derivatives as anticancer and anti-migratory agents | UNIVERSITY OF PUERTO RICO (US) | 2022-09-20 | — | — | US | disclosed |
| US-11446299-B2 | Carbazole EHop-016 derivatives as anticancer and anti-migratory agents | UNIVERSITY OF PUERTO RICO (US) | 2022-09-20 | — | — | US | disclosed |
| US-20200352941-A1 | NOVEL CARBAZOLE EHOP-016 DERIVATIVES AS ANTI-CANCER AND ANTI-MIGRATORY AGENTS | UNIV PUERTO RICO (US) | 2020-11-12 | — | — | US | disclosed |
| US-20200352941-A1 | NOVEL CARBAZOLE EHOP-016 DERIVATIVES AS ANTI-CANCER AND ANTI-MIGRATORY AGENTS | UNIV PUERTO RICO (US) | 2020-11-12 | — | — | US | disclosed |
| US-10729689-B2 | Carbazole EHop-016 derivatives as anti-cancer and anti-migratory agents | UNIVERSITY OF PUERTO RICO (US) | 2020-08-04 | — | — | US | disclosed |
| US-10729689-B2 | Carbazole EHop-016 derivatives as anti-cancer and anti-migratory agents | UNIVERSITY OF PUERTO RICO (US) | 2020-08-04 | — | — | US | disclosed |
| US-20190125746-A1 | NOVEL CARBAZOLE EHOP-016 DERIVATIVES AS ANTI-CANCER AND ANTI-MIGRATORY AGENTS | UNIVERSITY OF PUERTO RICO (PR) | 2019-05-02 | — | — | US | disclosed |
| US-20190125746-A1 | NOVEL CARBAZOLE EHOP-016 DERIVATIVES AS ANTI-CANCER AND ANTI-MIGRATORY AGENTS | UNIVERSITY OF PUERTO RICO (PR) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200352941-A1 | NOVEL CARBAZOLE EHOP-016 DERIVATIVES AS ANTI-CANCER AND ANTI-MIGRATORY AGENTS | CDC42, ARHGEF2, ARHGDIB | HSD17B10 2994/4885MEN1 1935/4885KMT2A 3497/4885 |
| US-11446299-B2 | Carbazole EHop-016 derivatives as anticancer and anti-migratory agents | CDC42, ARHGEF2, HRAS | HSD17B10 2736/4885MEN1 1521/4885KMT2A 3337/4885 |
| US-20190125746-A1 | NOVEL CARBAZOLE EHOP-016 DERIVATIVES AS ANTI-CANCER AND ANTI-MIGRATORY AGENTS | CDC42, ARHGEF2, HRAS | HSD17B10 3500/4885MEN1 2021/4885KMT2A 3051/4885 |
| US-10729689-B2 | Carbazole EHop-016 derivatives as anti-cancer and anti-migratory agents | CDC42, ARHGEF2, GDI2 | HSD17B10 2932/4885MEN1 1556/4885KMT2A 3509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.